PMID- 22192279
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20181015
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 163
IP  - 3
DP  - 2013 Mar 10
TI  - P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the 
      activated platelets.
PG  - 249-255
LID - S0167-5273(11)02145-0 [pii]
LID - 10.1016/j.ijcard.2011.11.088 [doi]
AB  - Primary percutaneous coronary intervention (PPCI) is the reperfusion method of 
      choice in ST elevation myocardial infarction (STEMI). However, STEMI represents a 
      highly pre-thrombotic state with platelets being greatly activated, so that an 
      effective adjunctive to PPCI antiplatelet treatment with P2Y12 inhibitors is 
      crucial in order to achieve an optimal reperfusion result. Clopidogrel has been 
      extensively used in clinical practice, although it may not be the ideal agent for 
      this condition due to its rather slow, weak and variable platelet inhibition 
      action. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have 
      been introduced recently and present a particularly favorable action profile for 
      the highly prethrombotic milieu of STEMI. The efficacy and safety issues with the 
      P2Y12 inhibitor use in STEMI and the possible role of phenotyping and/or 
      genotyping for appropriate agent selection are discussed and several clinically 
      important unanswered questions are raised.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Alexopoulos, Dimitrios
AU  - Alexopoulos D
AD  - Department of Cardiology, Patras University Hospital, Rion 26500, Patras, Greece. 
      Electronic address: dalex@med.upatras.gr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111220
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Purinergic P2Y Receptor Antagonists)
SB  - IM
MH  - Animals
MH  - Blood Platelets/drug effects/physiology
MH  - Clinical Trials as Topic/methods
MH  - Combined Modality Therapy/methods
MH  - Humans
MH  - Myocardial Infarction/metabolism/*therapy
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Activation/drug effects/*physiology
MH  - Purinergic P2Y Receptor Antagonists/pharmacology/*therapeutic use
EDAT- 2011/12/24 06:00
MHDA- 2013/12/16 06:00
CRDT- 2011/12/24 06:00
PHST- 2011/08/17 00:00 [received]
PHST- 2011/10/24 00:00 [revised]
PHST- 2011/11/26 00:00 [accepted]
PHST- 2011/12/24 06:00 [entrez]
PHST- 2011/12/24 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0167-5273(11)02145-0 [pii]
AID - 10.1016/j.ijcard.2011.11.088 [doi]
PST - ppublish
SO  - Int J Cardiol. 2013 Mar 10;163(3):249-255. doi: 10.1016/j.ijcard.2011.11.088. 
      Epub 2011 Dec 20.